'Vac­cines are not par­ti­san': White House ramps up de­liv­ery of bi­va­lent boost­ers

3 years ago
Coronavirus

Bay­er agrees to pay $40M to set­tle kick­back, safe­ty claims sparked by whistle­blow­er

3 years ago
Pharma
Law

Boehringer In­gel­heim preps FDA sub­mis­sion with new da­ta in rare pe­di­atric lung dis­ease

3 years ago
R&D
Pharma

Sun Phar­ma en­lists der­ma­tol­ogy HCPs to talk about per­son­al ac­ne ex­pe­ri­ences in new cam­paign

3 years ago
Pharma
Marketing

As­traZeneca ex­pands its block­buster Imfinzi fran­chise with new ap­proval in bil­iary tract can­cer

3 years ago
Pharma
FDA+

For­mer con­tract man­u­fac­tur­er CEO sen­tenced to prison for ship­ping con­t­a­m­i­nat­ed drugs to chil­dren's hos­pi­tals

3 years ago
Pharma
Manufacturing

Mar­ket­ingRx roundup: Pfiz­er boosts sci­ence with pop cul­ture takes on Face­book; BMS, Jazz de­but new SU2C teams

3 years ago
Pharma
Marketing

Noth­ing to laugh about: What hap­pened to hu­mor in phar­ma ad­ver­tis­ing?

3 years ago
Pharma
Marketing

Eye-fo­cused Iver­ic Bio re­ports pos­i­tive PhI­II read­out as shares surge, FDA fil­ing planned

3 years ago
R&D

FDA's out­side ex­perts to re­view GSK, As­traZeneca drugs; Biotech gives very ear­ly pos­i­tive in­di­ca­tions for cell ...

3 years ago
News Briefing

Up­dat­ed: Athi­ra plots an Alzheimer's come­back af­ter scan­dal, PhII fail — and hints at pos­si­ble ac­cel­er­at­ed ...

3 years ago
R&D
FDA+

Covid-19 roundup: CanSi­no’s in­haled vac­cine gets thumbs-up from Chi­nese reg­u­la­tors; Sino­vac gets go-ahead for ...

3 years ago
Coronavirus

On fi­nal dash to the clin­ic, Ar­se­nal­Bio hauls in $220M for 'mod­u­lar' cell ther­a­py ap­proach

3 years ago
Financing
Cell/Gene Tx

#ES­MO22: Dizal touts win in niche NSCLC pop­u­la­tion cor­nered by Take­da, J&J

3 years ago
R&D
China

Af­ter se­ri­ous side ef­fect, Sarep­ta and FDA re­align on next-gen Duchenne drug with tri­al hold lift­ed

3 years ago
FDA+

Alvotech fails pre-ap­proval in­spec­tion for its pro­posed Hu­mi­ra in­ter­change­able biosim­i­lar

3 years ago
Pharma
FDA+

Up­dat­ed: EU swats down Il­lu­mi­na's $8B Grail ac­qui­si­tion days af­ter FTC lost an­titrust case

3 years ago
Deals
Pharma

Seek­ing first-in-class glo­ry, Roche en­lists biotech part­ner that prides it­self on crack­ing 'un­drug­gable' tar­gets

3 years ago
Deals

Lat­est news on FDA’s sec­ond look at Amy­lyx; Un­pack­ing Parkin­son’s R&D; Fiona Mar­shall takes over NI­BR from Jay ...

3 years ago
Weekly

FDA again finds Amy­lyx's ALS da­ta lack­ing ahead of un­usu­al sec­ond ad­comm, while stress­ing dire need for treat­ments

3 years ago
Pharma
FDA+

FDA ex­pands ap­proval for Ver­tex's CF drug Orkam­bi to in­fants un­der two years of age

3 years ago
Pharma
FDA+

Biosim­i­lar gi­ant Bio­con gets hit with 483 for is­sues at sites in Malaysia and In­dia

3 years ago
FDA+
Manufacturing

Lead­ing health­care agency notch­es dou­ble-dig­it growth for first half, dri­ven by dig­i­tal shifts and full pipelines

3 years ago
Pharma
Marketing

Court win for Unit­ed Ther­a­peu­tics will re­strain loom­ing com­pe­ti­tion for its soon-to-be block­buster

3 years ago
Law
First page Previous page 467468469470471472473 Next page Last page
A service from the Financial Times